No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Breaking News: Contract research organizations are all on the rise, with Genscript Bio Technology leading the way with a 7.56% increase and WuXi AppTec with a 5.57% increase.
On August 6th, CXO concept stocks rose across the board. As of press time, Genscript Bio (01548.HK) rose 7.56% to HKD 12.8; Wuxi Apptec (02359.HK) rose 5.57% to HKD 35.05; Pharmaron (03759.HK) rose 3.64% to HKD 9.96; Wuxi Bio (02269.HK) rose 3.06% to HKD 11.44. The market source is from Futubull. On the news front, on August 6th, Daly of the Federal Reserve stated that the economy has been slowing down for the past few months; regarding the upcoming meeting in September.
The concept of contract research organizations is on the rise. Wuxi AppTec (02359) rose by 4.97%. Institutions predict that the performance of the pharmaceutical sector will show a marginal improvement trend.
Jingu Finance News | The concept of contract research organizations is up across the board. As of press time, Genscript Bio (01548) rose 6.07%, Wuxi AppTec (02359) rose 4.97%, Viva Biotech (01873) rose 4%, and Pharmaron (03759) rose 3.64%. On the news front, Xingye Securities issued a research report stating that the market attention to the pharmaceutical sector has gradually recovered recently. Looking back, the pharmaceutical sector experienced a downtrend of more than 2 months, with the CSI 300 Index down 11.0% (as of the close of August 2), while the Shanghai and Shenzhen 300 Index was also down 6.1% during the same period. Currently, the pharmaceutical sector is valued
Abnormal movement hits | CRO concept stocks lead the gains, the Fed's interest rate cuts will be bullish for CXO enterprise customers, and Shanghai issued a document supporting biomedical innovation.
On August 2nd, CRO concept stocks rose in early trading. As of press time, Tigermed (03347.HK) rose 5.67%, reporting 31.7 Hong Kong dollars; WuXi AppTec (02359.HK) rose 4.60%, reporting 33 Hong Kong dollars; Joinn Laboratories (06127.HK) rose 3.85%, reporting 7.56 Hong Kong dollars; Pharmaron (03759.HK) rose 3.80%, reporting 9.84 Hong Kong dollars. Market source: Futubull. On the news front, the Federal Reserve stated that if progress in combating inflation continues as desired, it may announce interest rate cuts at its September meeting. There are
No Data
